https://www.selleckchem.com/pr....oducts/aristolochic-
Medical treatment in benign prostatic hyperplasiatargets prostate size to prevent disease progression, complications, and surgery, and prostate smooth muscle tone for rapid relief of lower urinary tract symptoms. Combination therapies are still required to target both at once. However, current medications are insufficient, due to an unfavorable balance between side effects and efficacy. The limited efficacy of α -blockers may be due to nonadrenergic mediators like endothelin-1 and thromboxane A (TXA ), which keep up prostate
Like
Comment
Share
